The key idea is that acetylcholinesterase inhibitors improve muscle strength in myasthenia gravis. In MG, antibodies reduce the number or function of acetylcholine receptors at the neuromuscular junction, so transmission is weak and fatigable weakness occurs. When you give an acetylcholinesterase inhibitor, acetylcholine is increased in the synaptic cleft, temporarily enhancing receptor activation and strengthening the muscle response. This pharmacologic response—improved weakness after AChE inhibition—has historically been used to support a MG diagnosis and guides therapy with drugs like pyridostigmine. Immunoglobulin therapy, while important for crisis management or perioperative care, is not a diagnostic or hallmark pharmacologic response. Worsening after acetylcholinesterase inhibitors is not characteristic of MG and would prompt consideration of other issues such as a cholinergic crisis or different neuromuscular disorder.

Tandem walking is a balance and coordination test that uses a narrow base of support by having the patient place the heel of one foot directly in front of the toes of the other foot, forming a straight, narrow line. This precise alignment taxes motor planning, proprioception, and dynamic balance, so even mild cerebellar dysfunction or sensory ataxia shows up as unsteadiness, swaying, or stepping off the line. Walking heel-to-toe demonstrates this exact pattern, making it the best example. In contrast, walking across the room uses a wider base of support and isn’t challenging in the same way; walking on the toes and then the heels misses the continuous straight-line sequence; and walking with a shallow knee bend alters gait mechanics without embodying the tight heel-to-toe progression.

A progressive nervous system disorder that affects movement is best described by Parkinson's disease. It is a neurodegenerative condition characterized by the gradual loss of dopamine-producing neurons in the substantia nigra, which disrupts the nigrostriatal pathway and leads to motor symptoms such as resting tremor, rigidity, slowness of movement (bradykinesia), and postural instability. These features define a movement-dominant, progressively worsening picture. Delirium is an acute, fluctuating disturbance of consciousness and cognition, not a chronic neurodegenerative movement disorder. Alzheimer’s disease is primarily a dementia with early problems in memory and cognition, though it can progress to involve movement later; its hallmark is cognitive decline rather than the movement-centric presentation described here. Functional impairment is a broad term referring to decreased ability to perform tasks and does not name a specific progressive movement disorder.

The biceps reflex is mediated by the musculocutaneous nerve through spinal cord segments C5 and C6, so an abnormal reflex on the right points to dysfunction at those cervical roots. This is why the correct localization is C5-C6. The knee reflex involves lumbar segments L2-L4, the ankle reflex involves S1, and a focus on C6-C7 would not correspond to the primary innervation of the biceps reflex, making C5-C6 the best answer.

Movement is assessed by the motor response portion of the Glasgow Coma Scale. This part specifically looks at the patient’s best motor response to commands or to a painful stimulus, with a score range from 6 (obeys commands) down to 1 (no movement). It’s distinct from eye opening (how the eyes respond) and verbal response (what the patient can say or articulate). Pupillary or cranial nerve status aren’t part of the GCS scoring. So the component that measures motor function is the motor response.